RY 169.88 -1.0542% SHOP 144.59 -0.959% TD 77.85 -0.1667% ENB 59.62 -0.5505% BN 78.53 -0.971% TRI 223.92 -0.2495% CNQ 47.03 -0.0213% CP 102.49 -0.5627% CNR 147.77 -0.8787% BMO 131.32 -0.0685% BNS 78.4 0.0255% CSU 4463.7002 0.6222% CM 90.42 0.6344% MFC 44.91 -1.3184% ATD 77.0 -0.7604% NGT 60.01 -0.4149% TRP 68.0 -2.2989% SU 56.965 -0.4282% WCN 260.14 -0.653% L 176.45 0.7135%
Last update at 2024-11-20T19:19:00Z
A stronger Ozempic, Wegovy sales boom, and Hims' generic weight loss drug: Pharma news roundup
Fri 08 Nov 24, 10:00 AMHims & Hers will start selling a generic weight loss drug
Tue 05 Nov 24, 03:50 PMOzempic maker Novo Nordisk is working on a once-monthly weight-loss drug
Mon 04 Nov 24, 08:30 PMKnockoff weight loss drugs are having a moment. Eli Lilly isn't worried
Wed 30 Oct 24, 06:32 PMOzempic May Reduce the Risk of Alzheimer’s. That’s Huge for Novo Nordisk.
Thu 24 Oct 24, 02:37 PMOzempic maker Novo Nordisk wants the FDA to crack down on knockoff weight loss drugs
Wed 23 Oct 24, 06:04 PMNVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
Mon 21 Oct 24, 03:59 PMNVO's Alhemo Gets Positive CHMP Opinion in EU for Haemophilia A or B
Mon 21 Oct 24, 03:52 PMI'm a pharmacist. Knockoff Ozempic and other weight loss products have serious hidden risks
Mon 21 Oct 24, 01:55 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | 69062.00M | 59080.00M | 53130.00M | 48553.00M | 47615.00M |
| Minority interest | - | - | - | - | 0.00000M |
| Net income | 55525.00M | 47757.00M | 42138.00M | 38951.00M | 38628.00M |
| Selling general administrative | 4467.00M | 4050.00M | 3958.00M | 4007.00M | 3916.00M |
| Selling and marketing expenses | 46217.00M | 37008.00M | 32928.00M | 31823.00M | 29397.00M |
| Gross profit | 148506.00M | 117142.00M | 106014.00M | 101933.00M | 94214.00M |
| Reconciled depreciation | 7362.00M | 6025.00M | 5753.00M | 5661.00M | 3925.00M |
| Ebit | 74678.00M | 61531.00M | 54462.00M | 52130.00M | 47239.00M |
| Ebitda | 82040.00M | 67556.00M | 60215.00M | 57791.00M | 51164.00M |
| Depreciation and amortization | 7362.00M | 6025.00M | 5753.00M | 5661.00M | 3925.00M |
| Non operating income net other | - | - | - | - | 0.00000M |
| Operating income | 74809.00M | 58644.00M | 54126.00M | 52483.00M | 47248.00M |
| Other operating expenses | 102145.00M | 82156.00M | 72820.00M | 69538.00M | 64583.00M |
| Interest expense | 378.00M | 2451.00M | 390.00M | 220.00M | 85.00M |
| Tax provision | 13537.00M | 11323.00M | 10992.00M | 9602.00M | 8987.00M |
| Interest income | 239.00M | 231.00M | 337.00M | 65.00M | 51.00M |
| Net interest income | -320.00000M | -180.00000M | -203.00000M | -436.00000M | -106.00000M |
| Extraordinary items | - | - | - | - | 0.00000M |
| Non recurring | - | - | - | - | 0.00000M |
| Other items | - | - | - | - | 0.00000M |
| Income tax expense | 13537.00M | 11323.00M | 10992.00M | 9602.00M | 8987.00M |
| Total revenue | 176954.00M | 140800.00M | 126946.00M | 122021.00M | 111831.00M |
| Total operating expenses | 73697.00M | 58498.00M | 51888.00M | 49450.00M | 46966.00M |
| Cost of revenue | 28448.00M | 23658.00M | 20932.00M | 20088.00M | 17617.00M |
| Total other income expense net | -5427.00000M | 616.00M | -793.00000M | -3494.00000M | 473.00M |
| Discontinued operations | - | - | - | - | 0.00000M |
| Net income from continuing ops | 55525.00M | 47757.00M | 42138.00M | 38951.00M | 38628.00M |
| Net income applicable to common shares | 55525.00M | 47757.00M | 42138.00M | 38951.00M | 38628.00M |
| Preferred stock and other adjustments | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Total assets | 241257.00M | 194508.00M | 144922.00M | 125612.00M | 110769.00M |
| Intangible assets | 46324.00M | 38825.00M | 20657.00M | 5835.00M | 5145.00M |
| Earning assets | - | - | - | - | - |
| Other current assets | 2727.00M | 1690.00M | 2332.00M | 188.00M | 204.00M |
| Total liab | 157771.00M | 123762.00M | 81597.00M | 68019.00M | 58930.00M |
| Total stockholder equity | 83486.00M | 70746.00M | 63325.00M | 57593.00M | 51839.00M |
| Deferred long term liab | - | - | - | - | 0.00000M |
| Other current liab | 103887.00M | 76962.00M | 57097.00M | 51151.00M | 46893.00M |
| Common stock | 456.00M | 462.00M | 470.00M | 480.00M | 490.00M |
| Capital stock | 456.00M | 462.00M | 470.00M | 480.00M | 490.00M |
| Retained earnings | 80587.00M | 72004.00M | 63774.00M | 57817.00M | 53406.00M |
| Other liab | 12513.00M | 11285.00M | 8427.00M | 6027.00M | 4766.00M |
| Good will | 5092.00M | 4346.00M | - | - | 0.00000M |
| Other assets | 13633.00M | 8939.00M | 6539.00M | 4962.00M | 2893.00M |
| Cash | 12653.00M | 10720.00M | 12757.00M | 15475.00M | 15638.00M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 120940.00M | 99516.00M | 70273.00M | 58983.00M | 54164.00M |
| Current deferred revenue | 77378.00M | 55178.00M | 38727.00M | 35332.00M | 44869.00M |
| Net debt | 13131.00M | 15925.00M | -2401.00000M | -10992.00000M | -15123.00000M |
| Short term debt | 1466.00M | 13684.00M | 7459.00M | 1474.00M | 515.00M |
| Short long term debt | 480.00M | 12862.00M | 6684.00M | 659.00M | 515.00M |
| Short long term debt total | 25784.00M | 26645.00M | 10356.00M | 4483.00M | 515.00M |
| Other stockholder equity | -6.00000M | -6.00000M | -8.00000M | -10.00000M | -11.00000M |
| Property plant equipment | 66671.00M | 55362.00M | 50269.00M | 50551.00M | 41891.00M |
| Total current assets | 108194.00M | 85595.00M | 65809.00M | 62456.00M | 59067.00M |
| Long term investments | 1343.00M | 1441.00M | 1648.00M | 1808.00M | 1773.00M |
| Net tangible assets | 32070.00M | 27575.00M | 42668.00M | 51758.00M | 46694.00M |
| Short term investments | 10921.00M | 6765.00M | - | - | 0.00000M |
| Net receivables | 57505.00M | 46799.00M | 32184.00M | 29152.00M | 26889.00M |
| Long term debt | 20775.00M | 9654.00M | - | 3009.00M | 0.00000M |
| Inventory | 24388.00M | 19621.00M | 18536.00M | 17641.00M | 16336.00M |
| Accounts payable | 15587.00M | 8870.00M | 5717.00M | 6358.00M | 6756.00M |
| Total permanent equity | - | - | - | - | 0.00000M |
| Noncontrolling interest in consolidated entity | - | - | - | - | 0.00000M |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | 0.00000M |
| Accumulated other comprehensive income | 2449.00M | -1714.00000M | -911.00000M | -694.00000M | -2046.00000M |
| Additional paid in capital | - | - | - | - | 0.00000M |
| Common stock total equity | - | - | - | - | 0.00000M |
| Preferred stock total equity | - | - | - | - | 0.00000M |
| Retained earnings total equity | - | - | - | - | 0.00000M |
| Treasury stock | - | - | - | - | 0.00000M |
| Accumulated amortization | - | - | - | - | 0.00000M |
| Non currrent assets other | 412.00M | 534.00M | 1348.00M | 1682.00M | 51702.00M |
| Deferred long term asset charges | - | - | - | - | 0.00000M |
| Non current assets total | 133063.00M | 108913.00M | 79113.00M | 63156.00M | 51702.00M |
| Capital lease obligations | 4529.00M | 4129.00M | 3672.00M | 3824.00M | 0.00000M |
| Long term debt total | - | - | - | - | 0.00000M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -24918.00000M | -5941.00000M | -380.00000M | -299.00000M | 298.00M |
| Change to liabilities | 6717.00M | 3153.00M | -641.00000M | -398.00000M | 1146.00M |
| Total cashflows from investing activities | -24918.00000M | -31605.00000M | -22436.00000M | -11509.00000M | -12080.00000M |
| Net borrowings | -2408.00000M | 15471.00M | 4732.00M | -741.00000M | 94.00M |
| Total cash from financing activities | -51797.00000M | -25493.00000M | -32244.00000M | -35484.00000M | -34521.00000M |
| Change to operating activities | 2631.00M | 2185.00M | 5.00M | 441.00M | -932.00000M |
| Net income | 55525.00M | 47757.00M | 42138.00M | 38951.00M | 38628.00M |
| Change in cash | 1934.00M | -1507.00000M | -3185.00000M | -218.00000M | -1529.00000M |
| Begin period cash flow | 10719.00M | 12226.00M | 15411.00M | 15629.00M | 17158.00M |
| End period cash flow | 12653.00M | 10719.00M | 12226.00M | 15411.00M | 15629.00M |
| Total cash from operating activities | 78887.00M | 55000.00M | 51951.00M | 46782.00M | 44616.00M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 7362.00M | 6025.00M | 5753.00M | 5661.00M | 3925.00M |
| Other cashflows from investing activities | - | 4.00M | 18.00M | 20.00M | 19.00M |
| Dividends paid | -25303.00000M | -21517.00000M | -20121.00000M | -19409.00000M | 19048.00M |
| Change to inventory | -4767.00000M | -1085.00000M | -895.00000M | -1305.00000M | -963.00000M |
| Change to account receivables | -9917.00000M | -12909.00000M | -2822.00000M | -2126.00000M | -2621.00000M |
| Sale purchase of stock | -24086.00000M | -19447.00000M | -16855.00000M | -15334.00000M | -15567.00000M |
| Other cashflows from financing activities | 11215.00M | 22160.00M | 5682.00M | -11509.00000M | 94.00M |
| Change to netincome | 22145.00M | 10588.00M | 8890.00M | 6540.00M | 5433.00M |
| Capital expenditures | 14753.00M | 7385.00M | 22081.00M | 11231.00M | 12410.00M |
| Change receivables | - | - | - | - | 0.00000M |
| Cash flows other operating | - | - | - | - | 0.00000M |
| Exchange rate changes | - | - | - | - | 0.00000M |
| Cash and cash equivalents changes | - | - | - | - | 0.00000M |
| Change in working capital | -5336.00000M | -8656.00000M | -4353.00000M | -3388.00000M | -3370.00000M |
| Stock based compensation | 1539.00M | 1040.00M | 823.00M | 363.00M | 414.00M |
| Other non cash items | 6260.00M | -2489.00000M | -3402.00000M | -4407.00000M | -3968.00000M |
| Free cash flow | 64134.00M | 47615.00M | 29870.00M | 35551.00M | 32206.00M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| NONOF Novo Nordisk A/S |
2.44 2.38% | 105.00 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| NVO Novo Nordisk A/S |
2.89 2.82% | 105.52 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
0.44 0.10% | 448.45 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
-1.25 0.17% | 743.35 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
| CSLLY CSL Ltd |
0.43 0.49% | 88.73 | 42.45 | 26.95 | 7.05 | 5.80 | 7.85 | 26.51 |
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Novo Allé 1, Bagsvaerd, Denmark, 2880
| Name | Title | Year Born |
|---|---|---|
| Mr. Lars Fruergaard Jorgensen | Pres, CEO & Member of Management Board | 1966 |
| Mr. Karsten Munk Knudsen | Exec. VP, CFO & Member of the Management Board | 1971 |
| Mr. Henrik Ehlers Wulff | Exec. VP, Head of Product Supply, Quality & IT and Member of the Management Board | 1970 |
| Ms. Camilla Sylvest | Exec. VP, Head of Commercial Strategy & Corp. Affairs and Member of the Management Board | 1972 |
| Dr. Martin Holst Lange | Exec. VP, Head of Devel. & Member of the Management Board | 1970 |
| Ms. Monique Carter | Exec. VP, Head of People & Organisation and Member of Management Board | 1973 |
| Dr. Marcus Schindler Ph.D. | EVP, Head of Research & Early Devel., Chief Scientific Officer & Member of the Management Board | 1966 |
| Mr. Maziar Mike Doustdar | Exec. VP, Head of International Operations & Member of the Management Board | 1970 |
| Mr. Douglas J. Langa | Exec. VP, Head of North America Operations & Member of Management Board | 1966 |
| Mr. Ludovic Helfgott | Exec. VP, Head of Rare Disease & Member of Management Board | 1974 |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
CA 
AU
UK
US
NZ
Please wait processing your request...